- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Høyrisiko lokalisert prostatakreft in China
Totalt 410 resultater
-
The First Affiliated Hospital of Xiamen UniversityRekrutteringMetastatisk kastrasjonsresistent prostatakreft, mCRPCKina
-
Fudan UniversityUkjentProstatakreft MetastatiskKina
-
Shanghai Junshi Bioscience Co., Ltd.UkjentCOVID-19; og høy infeksjonsrisiko for SARS-CoV-2Kina
-
Affiliated Hospital to Academy of Military Medical...UkjentHøyrisiko bløtvevssarkomKina
-
Shanghai Jiao Tong University School of MedicineFudan University; Qilu Hospital of Shandong UniversityRekruttering
-
Lei LiUkjentLivmorhalskreft | Cervikal intraepitelial neoplasi | DNA-metylering | Cytologi | Høyrisiko humant papillomavirusKina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RekrutteringKjemoterapi effekt | DNA-skadereparasjonsmangel | Kjemoterapeutisk toksisitet | Hormonsensitiv metastatisk prostatakreftKina
-
Jiangsu HengRui Medicine Co., Ltd.FullførtHormonsensitiv prostatakreftKina
-
RenJi HospitalChanghai Hospital; Peking University People's Hospital; Shanghai Zhongshan... og andre samarbeidspartnereRekruttering
-
Shanghai General Hospital, Shanghai Jiao Tong University...NanoMab Technology (UK) LimitedFullført
-
Tianjin Medical University Second HospitalUkjent
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)Ukjent
-
Xinhua Hospital, Shanghai Jiao Tong University...Ukjent
-
West China HospitalRekrutteringKjemoradioterapi | Total Neoadjuvant Behandling | Local Advanced Rectal Cancer | High Risk FactorsKina
-
Luye Pharma Group Ltd.Har ikke rekruttert ennå
-
Peking Union Medical College HospitalRekruttering
-
Peking Union Medical College HospitalRekruttering
-
Peking Union Medical College HospitalRekruttering
-
Tianjin Medical University Second HospitalTianjin Medical University General Hospital; Tianjin First Central Hospital og andre samarbeidspartnereHar ikke rekruttert ennå
-
Luye Pharma Group Ltd.Fullført
-
Fudan UniversityAktiv, ikke rekrutterende
-
Second Military Medical UniversityPeking Union Medical College Hospital; RenJi Hospital; Zhejiang UniversityUkjent
-
Second Military Medical UniversityFullført
-
Ferring PharmaceuticalsFullført
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)Ukjent
-
The First Affiliated Hospital of Soochow UniversityRekrutteringHøyrisiko Akutt Myeloid Leukemi | Middels risiko Akutt myeloid leukemiKina
-
The First Affiliated Hospital with Nanjing Medical...RekrutteringMetastatisk prostatakreft | Terapi, direkte observertKina
-
Merck Sharp & Dohme LLCOrion Corporation, Orion PharmaRekrutteringProstatiske neoplasmer | Metastatisk kastrasjonsresistent prostatakreftKina
-
Fudan UniversityRekruttering
-
Shanghai East HospitalHar ikke rekruttert ennå
-
Peking Union Medical College HospitalRekruttering
-
Shanghai East HospitalHar ikke rekruttert ennå
-
Luye Pharma Group Ltd.Fullført
-
First Affiliated Hospital Xi'an Jiaotong UniversityRekruttering
-
First Affiliated Hospital Xi'an Jiaotong UniversityHar ikke rekruttert ennå
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...First Affiliated Hospital of Zhejiang University; The First Affiliated...Rekruttering
-
Qilu Hospital of Shandong UniversityZibo Central HospitalRekruttering
-
Xiangya Hospital of Central South UniversityRekruttering
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Rekruttering
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Ukjent
-
Lee's Pharmaceutical LimitedUkjent
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUkjent
-
The First Affiliated Hospital with Nanjing Medical...RekrutteringMetastatisk prostatakreft | Intermitterende anti-androgen terapiKina
-
BayerAvsluttetBenmetastaser | Metastatisk kastrasjonsresistent prostatakreftKina
-
Changhai HospitalRekruttering
-
Xinhua Hospital, Shanghai Jiao Tong University...Rekruttering
-
Jiangsu HengRui Medicine Co., Ltd.Påmelding etter invitasjonHormonreseptor positiv, human epidermal reseptor 2 negativ, nodepositiv, høyrisiko, tidlig stadium, brystkreft hos kvinnerKina